Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Equillium (EQ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Equillium, Inc. (EQ) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one ...

生物科技公司Equillium, Inc. (NASDAQ:EQ)，目前市值2,515万美元，股价0.71美元，今日宣布其用于治疗中重度溃疡性结肠炎(UC)的药物itolizumab二期临床试验取得积极结果。 根据InvestingPro数据显示，该公司资产负债表稳健，现金多于债务，但目前现金消耗速度较快。这项与Biocon Limited共同赞助的研究共纳入90名未使用过生物制剂的患者，随机分配 ...

The study was co-sponsored by Equillium and Biocon Limited and conducted at multiple clinical trial sites in India. The design and conduct of the trial were a collaborative effort, with input from ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...